High-mobility group box-1 (HMGB1) is a damage-associated molecular pattern (DAMP) increased in response to liver injury. Because HMGB1 is a ligand for the receptor for advanced glycation endproducts (RAGE), we hypothesized that induction of HMGB1 could participate in the pathogenesis of liver fibrosis though RAGE cell-specific signaling mechanisms. Liver 
the quality of life of these patients, and make headway in this field of research.
High-mobility group box-1 (HMGB1) is a damage-associated molecular pattern (DAMP) that rises in response to sterile and nonsterile tissue damage. (1) (2) (3) (4) Increased nuclear export due to injury drives HMGB1 cytoplasmic localization and ultimately secretion. (2, 5, 6) Our recent studies show that HMGB1 is up-regulated and secreted largely by hepatocytes and Kupffer cells (KCs), both anatomically located in close proximity to hepatic stellate cells (HSCs), the key profibrogenic cells in the liver. (1, 2) Hence, given that HMGB1 could be detrimental for neighboring cells, increased production by these two cellular sources could target HSCs to eventually elicit scarring. (1, 2, (7) (8) (9) (10) The receptor for advanced glycation endproducts (RAGE) is a multiligand receptor long implicated in homeostasis, development, and inflammation, is one of the main receptors for HMGB1. (11) RAGE engagement results in activation of numerous downstream signals impinging on canonical pathways that regulate transcription and translation as well as cell proliferation, survival, differentiation, and migration. Yet, the functional consequences of RAGE engagement and the signaling cascades turned on are strongly dependent on cell type, disease context, ligand identity, and local concentration that may also impact the composition and even organization of the liver matrisome. So far, the role of HMGB1 and how it signals in liver fibrosis has not been fully elucidated. In this study, our central hypothesis was that the cell-specific induction of HMGB1 could participate in the pathogenesis of liver fibrosis through RAGE cell-dependent mechanisms to up-regulate Collagen type I production in HSCs, thus contributing to scarring. We aimed to demonstrate this using human samples, several mouse models of liver fibrosis, along with genetic in vitro and in vivo complementary approaches.
Materials and Methods

HUMaN SaMpleS
Dr. Theise provided paraffin-embedded archival human liver biopsies from de-identified controls (healthy liver explants) and patients with clinically proven hepatitis C virus (HCV), primary biliary cirrhosis (PBC), or alcoholic steatohepatitis (ASH)-induced fibrosis, which were treatment naïve. The modified Ishak staging for fibrosis, which also parallels the Metavir staging system for chronic hepatitis, was used for HCV, (12) the Scheuer system for PBC, (13) and the Brunt classification for ASH. (40) 
StUDy appRoVal
Procurement of archived human samples was institutional review board approved, and no patient information was disclosed. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health. Housing and husbandry conditions were approved by our institutional animal care and use committee office before initiation of the studies. All in vivo experiments were carried out according to the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.
StatIStICal aNalySIS
Data are expressed as mean ± SEM. Statistical comparisons among groups and treatments in vitro were performed using a paired Student t test. All in vivo experiments were performed in triplicate, and data were analyzed by a two-factor analysis of variance, and the number of mice is indicated in the legend to each figure. Please see the Supporting Information.
Results
HepatIC HMgB1 pRoteIN eXpReSSIoN CoRRelateS WItH FIBRoSIS Stage IN CHRoNIC HCV, pBC, aND aSH patIeNtS
Because we hypothesized that HMGB1 could drive liver fibrosis, to determine whether there is correlation between HMGB1 induction, localization, and disease stage, we analyzed the expression of HMGB1 in archived human liver biopsies from de-identified healthy controls and patients with clinically proven HCV-induced fibrosis that advanced in disease stage (Scheuer/Batts-Ludwig classification). (12) Liver biopsies from HCV-infected patients showed progressive increase in HMGB1 protein expression with disease stage (Fig. 1A, first row) . Similar results were observed in patients with PBC or ASH (2) (Fig. 1A , second and third rows, respectively). Computer-assisted morphometry analysis demonstrated association between HMGB1 nucleocytoplasmic shuttling and fibrosis stage in all three conditions (2) (Fig. 1B) . Serum HMGB1 increased in patients with HCV (15.1 ± 3.1 ng/mL) and ASH (16.7 ± 6.6 ng/mL) compared to healthy individuals (1.1 ± 0.2 ng/mL). Therefore, the increase in HMGB1 expression, translocation into the cytoplasm, and secretion correlates with fibrosis progression in chronic HCV, PBC, and ASH (2) patients.
HepatIC HMgB1 pRoteIN eXpReSSIoN aND SeCRetIoN CoRRelateS WItH lIVeR FIBRoSIS IN MICe
To determine whether mouse models of liver fibrosis would mirror the above-mentioned findings in humans, we injected wild-type (WT) mice with mineral oil (MO) or CCl 4 for 1 month. Hematoxylin and eosin (H&E) staining, HMGB1 and Collagen type I immunohistochemistry (IHC), HMGB1 western blotting, and Collagen type I morphometry assessment revealed that CCl 4 increased HMGB1 and Collagen type I proteins compared to MO-injected mice (Fig. 1C) 1D , right), ASH (ad libitum and intragastric infusion "hybrid" feeding regime of high-cholesterol-fat diet and ethanol liquid diet with a weekly binge of alcohol (14) ; Supporting Fig. S1A , left) and nonalcoholic steatohepatitis (NASH; methionine-and choline-deficient diet [MCD]; Supporting Fig. S1A, right) .
Because HMGB1 translocation into the cytoplasm and ultimately secretion are critical for driving downstream events, (1, 2, (15) (16) (17) (18) (19) (20) its localization was quantified by morphometry analysis in all five models. As in humans, there was a significant increase in HMGB1 nucleo-cytoplasmic shuttling in all the fibrotic compared to their respective control mice ( Fig. 1E and Supporting Fig. S1B ). Importantly, liver and serum HMGB1 significantly increased in all fibrotic mice compared to their controls (Fig. 1E) . Hence, the rise in HMGB1 expression, translocation into the cytoplasm, and secretion correlates well with the extent of liver fibrosis in mice, too. Thus, HMGB1 could play a major role in the pathogenesis of liver fibrosis; yet, the cellular source of the protein, and how it acts as a profibrogenic factor, remains unknown.
IDeNtIFICatIoN oF tHe CellUlaR SoURCe oF HMgB1 IN lIVeR FIBRoSIS
To identify the precise hepatic cellular source of HMGB1 in liver fibrosis, immunofluorescence (IF) and colocalization studies were carried out using specific markers of HSCs (desmin, cytoplasmic), KCs Fig. 2A, C , and E; B, D, and F left). These findings were further confirmed by electrospray ionization/ liquid chromatography/mass spectrometry (ESI-LS-MS) in primary HSCs, KCs, and hepatocytes isolated from these mice (Fig. 2B,D,F, right) . There was minimal colocalization of HMGB1 with markers of ECs (Supporting Fig. S2A ,B) and some in BECs (Supporting Fig. S2C,D) under CCl 4 treatment. In summary, these in vivo results suggest that HMGB1 is highly induced in liver fibrosis, particularly in HSCs, KCs plus infiltrating macrophages, and hepatocytes; yet, if it plays a role in the pathogenesis of the disease and the specific mechanism whereby it could act as a profibrogenic, DAMP still remains to be defined.
NeUtRalIZatIoN oF HMgB1 pReVeNtS WHeReaS INJeCtIoN oF HMgB1 pRoMoteS lIVeR FIBRoSIS IN MICe
To dissect whether blocking HMGB1 prevents fibrogenic response to liver injury, WT mice were injected with nonimmune immunoglobulin G (IgG) or an HMGB1-neutralizing antibody (Ab) before each MO or CCl 4 dose for 1 month. Liver injury was assessed by H&E staining (Fig. 3A, first row) , the pathology scores (Fig. 3B, left) , and alanine FIg. 1. Hepatic HMGB1 protein expression correlates with fibrosis stage in chronic HCV, PBC, and ASH patients. IHC on formalinfixed, paraffin-embedded human liver biopsies from HCV, PBC, and ASH patients shows increased HMGB1 (400× oil, green arrow) expression with disease stage (A). Quantification of nuclear, cytoplasmic, and the ratios of nuclear-to-total and cytoplasmic-to-total HMGB1 protein expression in these patients according to disease stage. Results are given as fold-change of healthy liver explants assigned a value of 1 and are expressed as mean ± SEM; n = 10/disease and stage; *P < 0.05; **P < 0.01; ***P < 0.001 versus healthy (B). Hepatic HMGB1 protein expression and secretion correlates with liver fibrosis in mice. WT mice were injected MO or CCl 4 for 1 month. H&E staining (200×) shows greater necrosis (blue arrow) and inflammation (yellow arrow) in CCl 4 -than in MO-injected WT mice. IHC shows increased and translocated HMGB1 (400×, green arrows) and up-regulated Collagen type I expression (200×; perivenular fibrosis, closed pink arrow; bridging fibrosis, open pink arrow) in CCl 4 -compared to MO-injected WT mice (C, left). Western blotting of HMGB1 (C, top right) and total Collagen type I morphometry (C, bottom right) in MO-and CCl 4 -injected mice. Results are given as fold-change of MO-injected mice assigned a value of 1 and are expressed as mean ± SEM; n = 8/group; **P < 0.01; ***P < 0.001 versus MO. H&E (200×), HMGB1 (400×), and Collagen type I (200×) IHC in WT mice given water or TAA and with sham operation or BDL. Both treatments caused liver injury along with increased plus translocated HMGB1 and upregulated Collagen type I (D). Quantification of nuclear, cytoplasmic, and ratios of nuclear-to-total and cytoplasmic-to-total HMGB1 protein given as fold change of MO-injected mice assigned a value of 1. Total liver (AUC) and serum (ng/mL) HMGB1 quantified by ESI-LC-MS. Results are expressed as mean ± SEM; n = 8/group; *P < 0.05; **P < 0.01; ***P < 0.01 versus its own control (E). Abbreviation: ND, not detected. Given this, we asked whether injection of HMGB1, as a reverse approach, would enhance liver fibrosis. WT mice were injected with HMGB1 before each CCl 4 dose for 1 month. (21) H&E staining, HMGB1 expression, Collagen type I IHC, Sirius Red/fast green staining, the number of HSCs (Desmin + ) (Fig. 3D ), the pathology scores, total liver and serum HMGB1, morphometry, Collagen type I and αSMA western blotting, hepatic 4-hydroxyproline levels ( Fig. 3E) , fibrosis-related genes (Supporting Fig. S3A , bottom rows), and ALT activity ( , and hepatocytes (HNF4α protein-nuclear-and Hnf4a mRNA) (E,F). All panels are at 630× oil. Primary cells were isolated from these mice, and HMGB1 was quantified by ESI-LC-MS (AUC) (B,D,F, right). Results are expressed as mean ± SEM; n = 8/group; *P < 0.05; **P < 0.01 versus MO. Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; H, hepatocyte.
A C D B
injected with CCl 4 alone. Thus, HMGB1 increases fibrosis progression, but the mechanism whereby it occurs is still unknown.
HMGB1 aBlatIoN IN HepatoCyteS oR MyeloID CellS paRtIally pRoteCtS WHeReaS aBlatIoN IN BotH pReVeNtS CCl 4 -INDUCeD lIVeR FIBRoSIS
We have previously described the role of intracellular HSC-derived HMGB1 on Collagen type I expression in vitro.
(1) Here, we demonstrate that ablation of Hmgb1 in HSC in vivo using two different targeting strategies (i.e., Hmgb1 fl/fl Gfap-Cre and Hmgb1 fl/fl Lrat-Cre mice) confers some (~25%), yet not full, protection from hepatic fibrosis (Supporting Fig. S4 ), therefore pointing at a more prominent contribution of HMGB1 from other liver cell types.
Because we identified that the major sources of HMGB1 were hepatocytes and KCs plus infiltrating macrophages, to further establish whether hepatocyte-and/or myeloid cell-derived HMGB1 contributes to liver fibrosis, WT, Hmgb1
ΔHep , Hmgb1 ΔMye , and Hmgb1
ΔHepΔMye mice were injected with MO or CCl 4 for 1 month. Liver injury was assessed by H&E staining (Fig. 4A, first row) , the pathology scores (Fig. 4B, left) , and ALT activity (Fig. 4C) . HMGB1 expression was detected by IHC (Fig.  4A, second row) , the subcellular localization analyzed by morphometry, and quantified in liver and serum (Fig. 4D) . The extent of fibrosis was determined by Collagen type I IHC and Sirius Red/ fast green staining (Fig. 4A , third and fourth rows), morphometry (Fig. 4B, middle) , Collagen type I and αSMA western blotting, hepatic 4-hydroxyproline levels (Fig. 4E) , and fibrosis-related genes bridging fibrosis, open pink arrows) (A), the pathology scores, total liver (AUC) and serum (ng/mL) HMGB1, Collagen type I and Sirius Red/fast green morphometry, Collagen type I and αSMA western blotting, and 4-hydroxyproline content (B) and ALT activity (C) were significantly reduced in CCl 4 -injected mice pretreated with the HMGB1-neutralizing Ab compared to mice pretreated with nonimmune IgG. Results are expressed as mean ± SEM; n = 6/group; *P < 0.05, **P < 0.01; ***P < 0.001 versus CCl 4 + IgG. WT mice were injected CCl 4 . Pathology scores, total liver (AUC), and serum (ng/mL) HMGB1, Collagen type I and Sirius Red/fast green morphometry, Collagen type I and αSMA western blotting, and 4-hydroxyproline content (E). ALT activity (F). Results are mean ± SEM; n = 6/group; *P < 0.05; **P < 0.01 versus CCl 4 + albumin. Abbreviation: b. wt., body weight. (Supporting Fig. S3B ). All these parameters revealed partial protection from liver fibrosis in CCl 4 -injected Hmgb1
ΔHep or Hmgb1 ΔMye and almost full prevention in Hmgb1
ΔHepΔMye compared to WT mice. Vascularization (CD31; Fig. 4A , fifth row), the CD31 index (Fig. 4B, right) , and vascular endothelial growth factor (Vegf) mRNA (not shown) were alike in all groups of CCl 4 -injected mice, suggesting that changes in angiogenesis did not account for fibrosis stage in these mice. Importantly, because HMGB1 binds several receptors, including RAGE, Tolllike receptors (TLRs2/4/9), Mac-1, syndecan-1, phosphacan protein-tyrosine phosphatase-ζ/β, and CD24, (22) their expression was evaluated by qRT-PCR; however, no significant changes were found in any of the HMGB1 receptors' mRNA levels in livers from all MO-or CCl 4 -injected mice (not shown). Equal RAGE expression was confirmed by western blotting (Fig. 4E, bottom) . Overall, these findings suggest that Hmgb1 ablation in hepatocytes or myeloid cells partially protects, whereas ablation in both prevents, CCl 4 -induced liver fibrosis.
tWo aDDItIoNal MoUSe MoDelS CoNFIRM tHe Role oF HMgB1 IN lIVeR FIBRoSIS
To further prove the role of hepatocyte-and myeloid cell-derived HMGB1 in the CCl 4 model, we used two other well-established models of liver fibrosis. To this end, WT and Hmgb1
ΔHepΔMye mice were injected with TAA for 1 month or underwent BDL for 2 weeks. Liver injury was assessed by H&E staining (Supporting Fig. S5A , first row) and the pathology scores (Supporting Fig. S5B, left) . HMGB1 expression was detected by IHC (Supporting Fig. S5A , second row), the subcellular localization analyzed by morphometry and quantified in liver and serum (Supporting Fig. S5C ). The extent of fibrosis was determined by Collagen type I IHC (Supporting Fig.  S5A , third row) and morphometry (Supporting Fig.  S5B, right) . Together, the data demonstrated more liver injury, fibrosis, and ductular reaction in TAAtreated or BDL WT than in Hmgb1
ΔHepΔMye mice. Thus, these data confirm the results obtained in the CCl 4 model in two additional models of liver fibrosis.
HepatoCyteS aND KCs aRe a MaJoR SoURCe oF eXtRaCellUlaR HMgB1 SIgNalINg to HSCs to INCReaSe CollageN type I pRoDUCtIoN
Because the IHC from human and mouse liver suggested that hepatocytes and KCs plus infiltrating macrophages are a major source of HMGB1, (2) to further define their paracrine involvement in up-regulation of Collagen type I production by HSCs, cocultures of primary hepatocytes or KCs from MO-or CCl 4 -treated WT, Hmgb1
ΔHep
, and Hmgb1
ΔMye mice and WT HSC were established. Western blotting analysis demonstrated that coculture with hepatocytes or KCs from CCl 4 -injected WT mice significantly enhanced total Collagen type I expression in HSCs over that of MO-injected mice (Fig. 5A , lanes 2 and 6, total Collagen type I written in red); however, coculture with hepatocytes or KCs from CCl 4 -injected Hmgb1
ΔHep or Hmgb1
ΔMye , respectively, partially prevented this effect (Fig. 5A, lanes 4 and 8, total Collagen type I written in red). Total HMGB1 was quantified in cell lysate and culture medium from all cells seeded alone or in coculture. The culture medium from HSCs cocultured with hepatocytes ΔHep , Hmgb1
ΔMye , or Hmgb1 ΔHepΔMye mice. Vascularization (CD31, red staining, white arrows) was similar in all mice (A). Scores for necrosis, hepatocyte ballooning degeneration, inflammation, fibrosis, Collagen type I and Sirius Red/fast green morphometry, and CD31 index (B). Serum ALT (C). Quantification of nuclear, cytoplasmic, and ratios of nuclear-to-total and cytoplasmic-to-total HMGB1 protein given as fold change of MO-injected mice assigned a value of 1. Total liver (AUC) and serum (ng/mL) HMGB1 quantified by ESI-LC-MS (D). Western blotting analysis for Collagen type I, αSMA, and RAGE and quantification of 4-hydroxyproline (E). Results are expressed as mean ± SEM; n = 8/group; *P < 0.05; **P < 0.01; ***P < 0.001 versus WT + CCl 4 . Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; ND, not detected. from CCl 4 -injected mice showed a 5-fold increase in the concentration of HMGB1 compared to that from HSCs cocultured with KCs from CCl 4 -injected mice, suggesting that hepatocytes secrete more HMGB1 than KCs. Notably, HSCs also appeared to signal to hepatocytes and KCs in coculture to increase HMGB1 production and secretion, hence creating a profibrogenic loop (Fig. 5B) . Therefore, HSCs are responsive to hepatocyte-and KC-derived HMGB1 increasing total Collagen type I protein; yet, the receptor(s) involved and the signals conveyed to HSCs to up-regulate Collagen type I protein remain unknown.
HMgB1 StIMUlateS HSC MIgRatIoN WItHoUt alteRINg tHeIR VIaBIlIty oR Cell CyCle
To dissect whether HMGB1 could also affect the chemotaxis of HSCs, cells were treated with 0-1 nM ΔHep , and Hmgb1 ΔMye mice. Results are given as fold-change of the MO groups assigned a value of 1 and are expressed as mean ± SEM; n = 3/group; *P < 0.05; **P < 0.01; ***P < 0.001 versus MO or control and •P < 0.05; ••P < 0.01; •••P < 0.001 versus WT (A). Total cell lysate (AUC) and cell culture (ng/mL) HMGB1 in HSCs, hepatocytes, and KCs seeded alone or in coculture. In the HSC/ HEP and HSC/KC cocultures, the cell lysate is from hepatocytes and from KCs, respectively. Results are expressed as mean ± SEM; n = 3/group; **P < 0.01; ***P < 0.001 versus WT + MO (B). HMGB1 stimulates HSC migration without altering their viability or cell cycle. HSCs were treated with 0-1 nM of HMGB1 in the presence or absence of mitomycin for 24 hours. HSC migration is induced by HMGB1, but it is not fully prevented by cotreatment with mitomycin (C). HSC viability and cell cycle (D). n = 3/condition. Abbreviations: kDa, kilodaltons; ND, not detected. of HMGB1 for 24 hours in the presence or absence of mitomycin to inhibit mitosis. HMGB1 caused a significant increase in cell migration, an important function gained by HSCs during their activation that contributes to their profibrogenic phenotype. This result was specific because mitomycin blocked the effects of HMGB1 on HSC migration (Fig. 5C ). However, HMGB1 did not alter HSC viability or cell cycle (Fig. 5D ).
R AGE aBlatIoN IN HSCs aND Rage NeUtRalIZatIoN pReVeNt lIVeR FIBRoSIS IN VIVO
Among the receptors HMGB1 binds to, RAGE and TLR4 are expressed in HSCs and participate in liver fibrosis. (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) To establish the role of HSCs' RAGE in the effects mediated by HMGB1 in liver fibrosis, WT control, WT injected with a RAGEneutralizing Ab before CCl 4 , Tlr4
ΔHSC
, and Rage ΔHSC mice were treated with CCl 4 for 1 month. Liver injury was assessed by H&E staining (Fig. 6A, first row) , the pathology scores (Fig. 6B, left) , and ALT activity (Fig.  6C ). HMGB1 expression was detected by IHC (Fig.  6A, second row) , the subcellular localization analyzed by morphometry, and quantified in liver and serum (Fig. 6D) . Validation of the targeting strategy was demonstrated by colocalization of RAGE and Desmin in Rage ΔHSC mice (Fig. 6A, bottom left) and by colocalization of TLR4 and Desmin in Tlr4 ΔHSC mice (Fig. 6A, bottom right) . The extent of fibrosis was determined by Collagen type I IHC and Sirius Red/fast green staining (Fig. 6A, third and fourth rows) , morphometry (Fig. 6B, right) , Collagen type I and αSMA western blotting, hepatic 4-hydroxyproline levels (Fig. 6E) , and fibrosis-related genes (Supporting Fig.   S3C ). The results revealed a major reduction of fibrosis in WT with RAGE neutralization and in Rage ΔHSC , but minimal protection in Tlr4 ΔHSC mice, therefore validating the role of HMGB1 signaling by RAGE in HSCs for its profibrogenic effects. In addition, RAGE neutralization or ablation in HSCs reduced HMGB1 levels, further protecting the liver. To make sure that the protection observed in Rage ΔHSC mice was recapitulating protection attributed to lack of HMGB1 signaling through this receptor, we administered HMGB1 into WT mice treated with a RAGE-neutralizing Ab throughout the chronic CCl 4 treatment. Overall, our results suggest that blockade of RAGE signaling prevents the profibrogenic effect of HMGB1 (Supporting Fig. S6 ).
Because RAGE neutralization will block RAGE signaling in all liver cells expressing it, we then looked into whether Rage ablation in hepatocytes or myeloid cells could also protect from the profibrogenic effects of HMGB1 in the liver. WT, Rage
ΔHep
, and Rage ΔMye mice were injected CCl 4 for 1 month. Liver injury was assessed by H&E staining (Fig. 7A, first row) , the pathology scores (Fig. 7B, left) , and ALT activity (Fig.  7C ). HMGB1 expression was detected by IHC (Fig.  7A, second row) , the subcellular localization analyzed by morphometry, and quantified in liver and serum (Fig. 7D) . Validation of the targeting strategy was demonstrated by colocalization of RAGE and HNF4α in Rage ΔHep mice (Fig. 7A, bottom left) and by colocalization of RAGE and F4/80 in Rage ΔMye mice (Fig.  7A, bottom right) . The extent of fibrosis was determined by Collagen type I IHC and Sirius Red/fast green staining (Fig. 7A, third and fourth rows) , morphometry (Fig. 7B, right) , Collagen type I and αSMA western blotting, hepatic 4-hydroxyproline levels (Fig. 7E) , and fibrosis-related genes (Supporting Fig.   FIg. 6 . Rage ablation in HSCs and RAGE neutralization prevent liver fibrosis in vivo. WT control or intraperitoneally injected 0.4 µg/g b. wt. of RAGE neutralizing Ab (2 hours before CCl 4 ), Tlr4 ΔHSC , and Rage ΔHSC mice were injected with CCl 4 for 1 month. H&E staining (200×; necrosis, blue arrows; inflammation, yellow arrows), HMGB1 IHC (400× oil, green arrows), Collagen type I IHC and Sirius Red/fast green staining (200×; perivenular fibrosis, closed pink arrows; bridging fibrosis, open pink arrows), and colocalization of RAGE and TLR4 with Desmin (white arrows) (A). Scores for necrosis, hepatocyte ballooning degeneration, inflammation, fibrosis, Collagen type I, and Sirius Red/fast green morphometry (B). Serum ALT (C). Quantification of nuclear, cytoplasmic, and ratios of nuclear-to-total and cytoplasmic-to-total HMGB1 protein given as fold change of MO-injected mice assigned a value of 1. Total liver (AUC) and serum HMGB1 (ng/mL) quantified by ESI-LC-MS (D). Western blotting analysis for Collagen type I and αSMA and quantification of 4-hydroxyproline (E). Results are expressed as mean ± SEM; n = 8/group. *P < 0.05; **P < 0.01; ***P < 0.001 versus WT + CCl 4 . Abbreviations: b. wt., body weight; DAPI, 4',6-diamidino-2-phenylindole; ND, not detected. ΔMye mice showed reduced necrosis and ALT, but more inflammation (Fig. 7B) , perhaps pointing to a specific subset of immune cells infiltrating the liver to clear necrotic cells. 
HMgB1 SIgNalS tHRoUgH Rage to Up-RegUlate CollageN type I pRoteIN eXpReSSIoN IN HSCs
To dissect the mechanism involved in the increase in Collagen type I by HMGB1 in HSCs, first we evaluated whether the effect was receptor mediated. Upon successful Rage (Fig. 8A, left) or Tlr4 silencing (not shown), HSCs were challenged with 0-1 nM of HMGB1 for 24 hours. Western blotting analysis revealed that RAGE (Fig. 8, right) , but not TLR4 (not shown), was critical for effects of HMGB1 on Collagen type I increase in HSCs. Therefore, HMGB1 up-regulated Collagen type I in HSCs through RAGE; yet, the specific signal(s) transduced remained elusive. Because RAGE signaling leads to activation of protein kinases, to further investigate their contribution to the effects of HMGB1 on Collagen type I, we evaluated their expression in the presence of HMGB1. Western blotting analysis proved that HMGB1 phosphorylated mitogen-activated protein kinase kinase (MEK)1/2 and its downstream targets, (ERK)1/2 and cJun, besides activating phosphorylated protein kinase B (pAkt) signaling as previously identified by us.
(1) Both pathways are known to increase Collagen type I. (1, 35) Moreover, cJun, a component of the heterodimer, activator protein 1 (AP1), is a potent transactivating factor for the Col1a1 (36) and Col1a2 (37) genes. Importantly, these events were blocked in Rage -/-HSC (Fig.  8B) . Last, incubation of cells with the phosphorylated MEK1/2 (pMEK1/2) inhibitor, PD98095, blocked phosphorylated ERK1/2 (pERK1/2), pcJun, and pAkt at 30 minutes, and lowered intra-and extracellular Collagen type I at 24 hours (Fig. 8C) , suggesting that these two signaling pathways, with pMEK1/2 likely upstream of pAkt, were involved in the profibrogenic response to HMGB1 through RAGE in HSCs.
Discussion
Numerous mediators and signaling pathways that induce, propagate, and sustain liver fibrosis have been identified in the past; still, there is no definitive treatment for well-established fibrosis. This study addresses such an unmet need and challenges our current view of the mechanisms driving liver disease by reinforcing the role of HMGB1, an intrahepatic sterile DAMP, in the pathogenesis and progression of liver fibrosis. Here, we tested the hypothesis that during injury, hepatocytes and KCs plus infiltrating macrophages increase and secrete HMGB1, which acts as a paracrine alarmin through RAGE signaling in HSCs to up-regulate Collagen type I production to trigger and/or sustain scarring.
First, we highlighted that hepatic HMGB1 protein induction, translocation to the cytoplasm, and secretion correlate with fibrosis progression in patients with chronic HCV, PBC, and ASH and in five mouse models of liver fibrosis (CCl 4 , TAA, BDL, ASH, and diet-induced NASH). The overall contribution of HMGB1 to the pathogenesis of liver fibrosis was then demonstrated by injecting mice with an HMGB1 neutralizing Ab or recombinant HMGB1, which blunted or increased liver injury and fibrosis, respectively, thus stressing the significance of these findings. Overall, HMGB1 levels appear clearly associated with clinical outcome.
Second, we asked which cellular source of HMGB1 could drive fibrogenic response. We had previously described that whereas HSC secretion of HMGB1 is minimal, in response to an osteopontin (OPN) challenge or to increased endogenous production of OPN, as it occurs in liver fibrosis, HSCs are able to acetylate HMGB1 in vitro, an event that leads to Collagen type I deposition. In the present study, we show that HMGB1 also stimulates HSC migration in vitro and in vivo, contributing to progression of liver fibrosis. Importantly, we demonstrate that ablation of Hmgb1 in HSCs in vivo using two conditional targeting strategies partially (~25%) prevents scar formation. This finding unlocked the possibility that additional cellular sources of HMGB1 may have a more meaningful impact in liver fibrosis.
Next, we identified that hepatocytes and KCs plus infiltrating macrophages are the main hepatic cellular source of HMGB1 in the setting of liver fibrosis and that HSCs stimulate these cells to increase HMGB1 production, as shown in the coculture studies, therefore creating a profibrogenic loop. Because HMGB1 expression, nucleocytoplasmic shuttling, and secretion were maximal in hepatocytes followed by KCs plus infiltrating macrophages in mice with liver fibrosis, we endeavored to determine their specific and combined contribution to fibrogenesis in vivo. We show that ablation of Hmgb1 in hepatocytes or myeloid cells partially protects, whereas ablation in both prevents, CCl 4 -induced liver injury and fibrosis, which was validated in two additional mouse models of liver fibrosis (i.e., TAA and BDL). Likewise, we demonstrate that both cell types are a source of HMGB1 signaling to HSC to increase Collagen type I production. Mechanistically, we previously described that recombinant HMGB1 can bind RAGE in HSC in vitro and activate the phosphatidylinositol 3-kinase (PI3K)/pAkt signaling pathway to up-regulate Collagen type I production. (1) We have now identified that HMGB1 signals through RAGE in HSC in vivo to increase Collagen type I protein expression and that Rage, but not Tlr4, ablation in HSCs prevents liver fibrosis. RAGE engagement by HMGB1 leads to phosphorylation and thus activation of the MEK1/2, ERK1/2, and cJun signaling pathway that up-regulates Collagen type I protein expression (Fig. 8D ). This pathway is relevant for liver fibrosis because it also drives transforming growth factor beta (TGFβ) production and signaling through small mothers against decapentaplegic 2 and 3 (SMADs) in HSCs feeding back into the MEK1/2, ERK1/2 and cJun pathway (38, 39) in addition to TGFβ also being known for stimulating HSC migration. (40) Notably, phosphorylation of MEK1/2 occurred within 30 minutes, with a subsequent increase in Collagen type I within 24 hours. Given that PD98095 inhibited pMEK1/2 and this caused a blockade of pAkt, pMEK1/2 is likely upstream of pAkt in regulating Collagen type I production.
The specificity of HMGB1 signaling through RAGE in HSCs in vivo was further confirmed by coinjecting a RAGE-neutralizing Ab along with HMGB1 to WT mice or by using Rage ΔHSC mice Western blotting for pMEK1/2, pERK1/2, ERK1/2, pcJun, pAkt1/2/3, Akt, RAGE, and Actin (B). HSCs were treated with 0-2 µM of PD98095 for 1 hour before the addition of 0-1 nM of HMGB1. Samples were analyzed by western blotting for pMEK1/2, pERK1/2, total ERK1/2, pcJun, pAkt1/2/3 473 Ser, total Akt1/2/3, RAGE, and actin at 30 minutes (C, top) and for Collagen type I and Calnexin at 24 hours (C, bottom). Results are given as fold-change of the control or WT HSCs assigned a value of 1 and are expressed as mean ± SEM (omitted under the blots because of lack of space); numbers under the blottings are ratios of any given protein expression against the specific internal loading control or the native protein. n = 3/group; *P < 0.5; **P < 0.01; ***P < 0.001 versus control and •P < 0.05; ••P < 0.01; •••P < 0.001 versus WT HSC or HMGB1 treated. Working model: We previously showed that intracellular acetylation of HMGB1 attributed to OPN stimulation in HSCs also contributes to Collagen type I deposition. (1) We now demonstrate that during liver fibrosis, hepatocytes and KCs plus infiltrating macrophages increase HMGB1 expression and secretion. Extracellular HMGB1 binds RAGE on HSCs and activates both the pMEK1/2, pERK1/2 and pcJun and the PI3K/pAkt signaling pathways to up-regulate Collagen type I production. pMEK1/2 appears to be upstream of pAKT in these events. Rage ablation in HSCs or RAGE neutralization prevents the HMGB1-mediated effects on HSCs to up-regulate Collagen type I production, hence preventing fibrosis. Notably, Rage ablation in HSCs or neutralization reduces HMGB1 production by hepatocytes and myeloid cells through unknown mechanisms, further protecting the liver. (Note that the strategies we used to prove each step have been integrated in the working model and are written using black font.) Abbreviations: Akt, protein kinase B; DMSO, dimethyl sulfoxide; HDACs1/2, histone deacetylases 1 and 2; kDa, kilodaltons; MMP1, matrix metalloproteinase 1; OPN, osteopontin; rHMGB1, recombinant HMGB1. production by hepatocytes and myeloid cells, although the potential mediator and/or mechanisms involved still remain to be determined. Of note, Rage ablation in myeloid cells triggered an unexpected surge in the number of inflammatory cells, which perhaps resulted from either HMGB1 per se or from other RAGE ligands increasing their extravasation into the liver, maybe to phagocytose necrotic cells. Posttranslational modifications of HMGB1 and their association with proinflammatory events that drive fibrosis are currently under active investigation in our laboratory and may also be critical in this setting.
Last, we are aware that some discrepancy may exist between the potential role of TLR4 in liver fibrosis previously suggested by others (41) and our findings. An explanation may be that our studies used conditional ablation of Tlr4 in HSCs in vivo. Moreover, a delipidated LPS-binding region in position 3-15 and a lipid A-binding region in position 80-96 containing four and one acetylation sites, respectively, have been predicted in HMGB1; thus, it is also possible that HMGB1 sequesters lipopolysaccharide, precluding it from binding to TLR4, which could be further regulated by protein acetylation; yet, this has not been proven. It is also conceivable that lack of TLR4 in HSCs causes a paracrine effect on neighboring cells that sustains fibrosis. Finally, it is possible, though more speculative, that in some settings HMGB1 may enhance TLR4 expression, which could sustain TLR4 signaling in key cells such as KCs and infiltrating macrophages. Whereas these studies suggest a more prominent role for RAGE, and specifically HSCs' RAGE, in fibrosis onset and progression, we do not rule out that in the later stages of the disease, when HMGB1 undergoes posttranslational modifications, or even during fibrosis resolution, TLR4 may be part of the picture. Nonetheless, although the RAGE binding site has been localized to residues 150-183 in HMGB1, the TLR4 binding site has not been identified so far.
In conclusion, the increase in hepatic HMGB1 during fibrogenesis contributes to the pathogenesis of the disease by driving scar formation. HMGB1, unlike other profibrogenic mediators, provides a much wider time frame for clinical intervention attributed to its remarkable cellular mobility, prolonged half-life, and, accordingly, longer receptor activation. (3) Hence, the increase in HMGB1 is not a mere result of liver damage, but also a contributing event and thus a possible target to prevent the onset and progression of liver fibrosis. It is hoped that this concept could have great impact for the detection and potentially the treatment of liver fibrosis in patients.
